A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.
Also called NCT01065454
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 202 participants
- Sponsor
- Registry
-
NCT01065454 -
2009-015878-35
-
- Main results
- Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Singapore, Spain, Switzerland, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01065454. Randomized; quadruple masking; primary purpose treatment. Start 2010-04-14 (actual); primary completion 2012-06-06 (actual). Results posted on 2013-12-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
- Acronym
- LEPHT
- Condition
- Hypertension, Pulmonary
- Condition
- Ventricular Dysfunction, Left
- Intervention (Drug)
- Riociguat (Adempas, BAY63-2521)
- Intervention (Drug)
- Riociguat (Adempas, BAY63-2521)
- Intervention (Drug)
- Riociguat (Adempas, BAY63-2521)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01065454- Content hash
1e372135436a983a490c8f880df9bbe81614e94511f768238eeb0ae5b3548915